Editor’s note

  • Does IP build or block?

    Its been 17 years since the World Intellectual Property Organisation (WIPO) started marking April 26 as World Intellectual Property Day

  • US-India relationship: Can it trump the odds?

    Affordable and efficient healthcare systems is listed out as an area chosen for “Growing Convergence, Collaboration & Cooperation between United States and India” in a...

  • Collaborate to conquer

    Two rulings in the space of as many days demonstrate the fine balance required of India’s legal system when it comes to the pharmaceutical sector

  • Evolving an ‘India First’ policy

    The countdown to the USTR for 2017 Special 301 Review has begun

  • Beyond the budget

    The hype around the Union Budget 2017-18, especially after Prime Minister Modi's December 31 address was high but the general consensus is that it has...

  • Pharma PSUs: Missed opportunity?

    The turnover of the Indian pharmaceutical industry was estimated at Rs 2,04,627.1 crores in FY2015-16, registering a growth of 29 per cent compared to the...

  • Giving with a purpose

    ‘He who has health, has hope; and he who has hope, has everything,’ said Thomas Carlyle, social commentator and philosopher

  • More pain before the gain

    An ICRA quarter update on the pharmaceutical sector does not have very encouraging news for 2017

  • Girding up for a VUCA world

    The term VUCA, an acronym for volatility, uncertainty, complexity and ambiguity, was reportedly first coined by the US Army War College to describe the condition...

  • More power to GST

    The ongoing winter session of Parliament is crucial as there are many big ticket bills awaiting a nod

  • India Pharma Inc’s Trump card

    Donald J Trump has beaten all odds to win the US election, much like the Indian pharmaceutical industry’s hard won rise as the go-to country...

  • In search of sustainable growth

    When Ministers speak like CEOs, industry sits up and listens. The relatively newly minted state of Telangana is racing to catch up to its peers...

  • Abiding by the rules

    The debate about replacing PET packaging with glass as packaging material for pharmaceuticals is reaching yet another milestone as the matter is due to come...

  • Opportunities amidst challenges

    MSF’s seven-year-old appeal campaign to reduce flu vaccine prices has finally borne fruit

  • Reviving APIs

    Even as Indian pharmaceutical companies pursue aggressive plans for global expansion, there are deep challenges in the domestic market

  • Thriving through change

    A recently released analysis of the global courier industry from 2010-2021, shows that the pharmaceutical sector accounts for just seven per cent of the sector's global...

  • Testing the new FDI norms

    The Modi government’s reforms have tinkered with FDI norms twice, first in November 2015 and more recently in June this year

  • Turning threat into opportunity

    It is human nature to perceive change as a threat. But turning this threat into an opportunity is a crucial skill

  • Back to the basics

    After taking a beating from overseas regulators for the past few years, analysts are finally sounding marginally cautious about the fortunes of pharma companies in...

  • Redrawing the Lakshman rekha

    A national IPR policy, new FDI norms, a possible revamp of the Drugs & Cosmetics Act, Brexit: the pharma sector in India has a lot...

  • Betting big on M&As

    Dr Reddy's Laboratories' June 11 announcement that it had entered into an agreement with Teva and Allergan to buy eight Abbreviated New Drug Applications (ANDAs)...

  • Moving up the green ladder

    As the Modi Government launches its second anniversary celebration on May 26, the BJP will be organising 200 odd events over a fortnight, accompanied by...

  • Embracing quality as an opportunity

    Concerned with declining pharma exports in the recent past, the Ministry of Commerce & Industry has tried to burnish the brand image of India's pharmaceutical...

  • To switch or not to switch …

    A notice dated March 30 from the Drug Controller General (India) asking for ‘science-based suggestions/ comments’ on the pros and cons of replacing animal-based gelatin capsules...

  • Quality consciousness: A pre-requisite to progress

    Manufacturing quality has now become probably the single most important concern in the boardrooms of pharmaceutical companies in India

  • Weeding out the bad FDCs

    The fixed dose combination (FDC) issue has been a contentious one for years and on March 10 came back to haunt pharma companies in India

  • Once again, nothing much for pharma

    In his third budget, Finance Minister Arun Jaitley has taken one more shot at a balancing act between maintaining fiscal discipline and loosening the purse...